Skip to main content
. Author manuscript; available in PMC: 2017 Sep 21.
Published in final edited form as: Bioconjug Chem. 2016 Sep 2;27(9):2157–2165. doi: 10.1021/acs.bioconjchem.6b00374

Figure 4.

Figure 4

Whole body imaging of tumor-bearing mice 2h following tail vein injection of 2 nmol of NKlRL-Peptide-LS288. Mice implanted with a NK1R tumor (a-d) and KB tumor (e-f) were injected NKlRL-Peptide-LS288 in the absence (a, b, e, f) or presence (c, d) of 100-fold excess of ligand 3. Note that KB tumors express no NK1 receptor (negative control). Tumors are shown with red arrows.